MAIA Biotechnology, Inc. (MAIA): Total Liabilities
$7.33M
As of 2025-12-31
$7.57M
As of 2026-06-30
+27.8%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.33M | +12.4% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $6.52M | -8.0% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $7.09M | +101.7% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $3.51M | +63.8% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $2.15M | n/a | 2023-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $7.33M | +12.4% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $3.38M | -14.0% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $3.46M | -74.7% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $2.49M | -94.2% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $10.02M | +299.0% |
| Oragenics Inc (OGEN) | 2025-12-31 | $1.79M | +6.1% |
| Indaptus Therapeutics, Inc. (INDP) | 2024-12-31 | $3.39M | +19.2% |
| Genprex, Inc. (GNPX) | 2025-12-31 | $2.20M | -12.3% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $3.94M | -18.7% |
Compare MAIA, COCP, FBLG, KALA side by side · Screen every company in Pharmaceutical Preparations ↗